1 Result: Acelyrin
Acelyrin (SLRN), CRISPR Therapeutics (CRSP), Elevation Oncology (ELEV), STERIS (STE), Teleflex (TFX): Analyst Coverage and Potential Upside Revealed
May 30th, 2023
Acelyrin, Inc. (Nasdaq: SLRN), a pharmaceutical company dedicated to developing innovative therapies, caught the attention of Jefferies, which initiated coverage on the stock with a Buy rating and a price target of $31. Despite $SLRN closing. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Wall Street Eyes Ciena, lululemon, and Broadcom Ahead of Earnings
December 07th, 2025Earnings Watch: What to Expect from Electrovaya, Nordson, and Synopsys
December 07th, 2025Earnings on Deck: AeroVironment, AutoZone, and Core & Main Set to Report
December 07th, 2025December 05th, 2025FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025
Member Login